Associate Professor Natalie Staplin
MRC PHRU Senior Statistician
Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences. She joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics. Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease. She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
LANDRAY M. et al, (2021), The Lancet
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Horby P. et al, (2021), Lancet, 398
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2021), JAMA
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter-2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter-2 inhibitors
HERRINGTON W. et al, (2021), European Journal of Heart Failure
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group None. et al, (2021)